Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...
Douglas L. Mann, MD, professor of medicine at Washington University School of Medicine in St. Louis and editor-in-chief of JACC: Basic to Translational Science discussed the first set of data reported ...
Please provide your email address to receive an email when new articles are posted on . According to a non-trial, published in JACC: CardioOncology, in unselected patients, serum transthyretin change ...
Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ...
OXFORD, England, Jan. 10, 2024 /PRNewswire/ -- Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with ...
For asymptomatic patients diagnosed with early-stage transthyretin amyloid cardiomyopathy (ATTR-CM), it can take just a few years to progress to clinical heart failure or other cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback